Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Diagnostic Pathology
Published in: Diagnostic Pathology 1/2020

01-12-2020 | Bladder Carcinoma | Research

ROC-1, P21 and CAIX as markers of tumor aggressiveness in bladder carcinoma in Egyptian patients

Authors: Dalia Rifaat Al-Sharaky, Mona Abd El-Halim Kandil, Hayam Abdel Samie Aiad, Enas Megahed El-hosary, Hagar Abdelmagied Alagizy, Mahmoud Abdel-Sattar Elshenawy, Hala Said El-Rebey

Published in: Diagnostic Pathology | Issue 1/2020

Login to get access

Abstract

Background

Bladder cancer (BC) is one of the most common malignancies in Egypt, representing about 8.7% of cancers in both sexes with more predominance in males, making identification of valuable predictive and prognostic markers, mandatory. Cullin-RING ligases (CRL) play an important role in the ubiquitination of cell cycle-related proteins or other proteins (e.g., DNA replication protein, signal transduction protein). Regulator of Cullins-1 (ROC-1) is a key subunit of CRL. P21 belongs to the family of cyclin dependent kinase inhibitors (CKIs) which regulates cell cycle by inactivating Cyclin- Dependent Kinases key regulators of the cell cycle. CAIX a highly active member of the family of carbonic anhydrases has gained much interest as a hypoxic marker. Hypoxia is a consequence of the rapid growth of many tumors, including bladder cancer, and is an important regulator of gene expression and resistance to chemotherapy and radiotherapy. Therefore the purpose of this study is to evaluate the role of ROC-1, CAIX and P21 and its relationship with the clinico-pathological features of bladder cancer in Egyptian patients.

Methods

Using the standard immunohistochemical technique, ROC-1, CAIX and P21 expression in 80 primary bladder carcinomas and 15 normal bladder specimens as control group were assessed. The bladder carcinoma cases included 50 cases with muscle invasive bladder cancer and 30 cases with non-muscle invasive bladder cancer.

Results

Over expression of ROC-1, CAIX and P21 in BC were significantly associated with muscularis propria invasion and high grade BC. ROC-1, CAIX and P21, showed significant inverse relationship in primary BC cases. CAIX expression was significantly higher in BC compared with controls. Regarding the survival analysis, expression of ROC-1, CAIX and P21 didn’t affect the survival of BC patients.

Conclusions

High expression of ROC-1, CAIX and P21 could be promising potential biomarkers for identifying patients with poor prognostic factors in bladder cancer serving as potential targets for cancer therapy.
Literature
1.
2.
3.
Petroski MD, Deshaies RJ. Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol. 2005;6:9–20.PubMedCrossRef
4.
Jia L, Soengas MS, Sun Y. ROCI/RBX1 E3 ubiquitin ligase silencing suppresses tumor cell growth via sequential induction of G2-M arrest, apoptosis, and senescence. Cancer Res. 2009;69:4974–82.PubMedPubMedCentralCrossRef
5.
6.
Wang W, Qiu JX, Liu Z, Guo Y, Zeng Y, Fan J, et al. Overexpression of RING box protein-1 (RBX1) associated with poor prognosis of non-muscle-invasive bladder transitional cell carcinoma. J Surg Oncol. 2013;107:758–61.PubMedCrossRef
7.
Bartek J, Lukas J. DNA damage checkpoints: from initiation to recovery or adaptation. Curr Opin Cell Biol. 2007;19:238–45.PubMedCrossRef
8.
9.
Moch H, Humphrey PA, Ulbright TM, Reuter V, editors. Tumors in urinary tract. WHO classification of tumours of the urinary system and male genital organs. Lyon: International Agency for Research on Cancer; 2016. p. 78–130.
10.
Chauhan R, Verma N, Sharma SP, Bhargava R, Singh P. Role of apoptotic index, mitotic index and MIB-1 antibody expression as biomarkers in preneoplastic and neoplastic lesions of uterine cervix. Int J Res Med Sci. 2016;4(6):2093–100.CrossRef
11.
12.
Shariat SF, Kim J, Rapitidis G, Ayala GE, Lerner SP. Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology. 2003;61:1140–5.PubMedCrossRef
13.
Trastour C, Benizri E, Ettore F, Ramaioli A, Chamorey E, Pouyssegur J, et al. HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. Int J Cancer. 2007;120:1451–8.CrossRefPubMed
14.
Dawson B, Trapp R, editors. Basic and clinical biostatistics: large medical books. Oxford: Boston; 2001. p. 270–5.
15.
Migita K, Takayama T, Matsumoto S, Wakatsuki K, Tanaka T, Ito M, et al. Prognostic impact of RING box protein-1 (RBX1) expression in gastric cancer. Gastric Cancer. 2014;17:601–9.PubMedCrossRef
16.
17.
Randle SJ, Laman H. F-box protein interactions with the hallmark pathways in cancer. Semin Cancer Biol. 2016;36:3–17.PubMedCrossRef
18.
Wang W, Chen H, Liu Z, Qu P, Lan J, Chen H, et al. Regulator of cullins-1 expression knockdown suppresses the malignant progression of muscle-invasive transitional cell carcinoma by regulating mTOR/DEPTOR pathway. Br J Cancer. 2016;114:305–13.PubMedPubMedCentralCrossRef
19.
Gong X, Litchfield LM, Webster Y, Chio LC, Wong SS, Stewart TR, et al. Genomic aberrations that activate D-type cyclins are associated with enhanced sensitivity to the CDK4 and CDK6 inhibitor Abemaciclib. Cancer Cell. 2017;32(6):761–76.PubMedCrossRef
20.
Gherardi E, Birchmeier W, Birchmeier C, VandeWoude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012;12:89–103.PubMedCrossRef
21.
22.
Gordon EM, Laumann TO, Adeyemo B, Huckins JF, Kelley WM, Petersen SE. Generation and evaluation of a cortical area Parcellation from resting-state correlations. Cereb Cortex. 2016;26:288–303.PubMedCrossRef
23.
24.
Ueno H, Shinto E, Kajiwara Y, Fukazawa S, Shimazaki E, Yamamoto J. Prognostic impact of histological categorisation of epithelial–mesenchymal transition in colorectal cancer. Br J Cancer. 2014;111:2082–90.PubMedPubMedCentralCrossRef
25.
Lundgren K, Holm C, Landberg G. Hypoxia and breast cancer: prognostic and therapeutic implications. Cell Mol Life Sci. 2007;64:3233–47.PubMedCrossRef
26.
Zhou W, Dosey TL, Biechele T, Moon RT, Horwitz MS, Ruohola-Baker H. Assessment of hypoxia inducible factor levels in cancer cell lines upon hypoxic induction using a novel reporter construct. PLoS One. 2011;6:e27460.PubMedPubMedCentralCrossRef
27.
28.
Shariat SF, Alexandre RZ, Raheela A, Arthur IS, Yair L. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol. 2007;20:445–59.PubMedCrossRef
29.
Liu X, Yu H, Cai H, Wang Y. Expression of CD24, p21, p53, and c-myc in alpha-fetoprotein-producing gastric cancer: correlation with clinicopathologic characteristics and survival. J Surg Oncol. 2014;109:859–64.PubMedCrossRef
30.
Huang WJ, Jeng YM, Lai HS, Fong IU, Sheu FY, Lai PL, Yuan RH. Expression of Hypoxic Marker Carbonic Anhydrase IX Predicts Poor Prognosis in Resectable Hepatocellular Carcinoma. PLoS One. 2015;10(3):e0119181.PubMedPubMedCentralCrossRef
31.
Han J, Wang F, Yuan SQ, Guo Y, Zeng ZL, Li LR, et al. Reduced expression of p21-activated protein kinase 1 correlates with poor histological differentiation in pancreatic cancer. BMC Cancer. 2014;14:650.PubMedPubMedCentralCrossRef
32.
Xie D, Lan L, Huang K, Chen L, Xu C, Wang R, et al. Association of p53/p21 expression and cigarette smoking with tumor progression and poor prognosis in non-small cell lung cancer patients. Oncol Rep. 2014;32:2517–26.PubMedCrossRef
33.
Tang K, Wang C, Chen Z, Xu H, Ye Z. Clinicopathologic and prognostic significance of p21 (Cip1/Waf1) expression in bladder cancer. Int J Clin Exp Pathol. 2015;8(5):4999–5007.PubMedPubMedCentral
34.
35.
Dai L, Liu Y, Liu J, Wen X, Xu Z, Wang Z, et al. A novel CyclinE/CyclinA-CDK inhibitor targets p27Kip1 degradation, cell cycle progression and cell survival: implications in cancer therapy. Cancer Lett. 2013;333:103–12.PubMedCrossRef
36.
De Renty C, De Pamphilis ML, Ullah Z. Cytoplasmic Localization of p21 Protects Trophoblast Giant Cells from DNA Damage Induced Apoptosis. PLoS One. 2014;9:e97434.PubMedPubMedCentralCrossRef
37.
Cheng X, Xia W, Yang JY, Hsu JL, Chou CK, Sun HL, et al. Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. Biochem Biophys Res Commun. 2010;403:103–7.PubMedPubMedCentralCrossRef
38.
Diaz-Moralli S, Tarrado-Castellarnau M, Miranda A, Cascante M. Targeting cell cycle regulation in cancer therapy. Pharmacol Ther. 2013;138:255–71.PubMedCrossRef
39.
Klatte T, Seligson DB, Rao JY, Yu H, de Martino M, Kawaoka K, et al. Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker. Cancer. 2009;115:1448–58.PubMedCrossRef
40.
Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000;15(60):7075–83.
41.
PC MD, Winum JY, Supuran CT, Dedhar S. Recent Developments in Targeting Carbonic Anhydrase IX for Cancer Therapeutics. Oncotarget. 2012;3:84–97.
42.
Hunter BA, Eustace A, IrlamJ J, Valentine HR. DenleyH, OguejioforK K, et al. expression of hypoxia-inducible factor-1α predicts benefit from hypoxia modification in invasive bladder cancer. Br J Cancer. 2014;111:437–43.PubMedPubMedCentralCrossRef
43.
Finkelmeier F, Canli O, Peiffer K-H, Walter D, Tal A, Koch C, et al. Circulating hypoxia marker carbonic anhydrase IX (CA9) in patients with hepatocellular carcinoma and patients with cirrhosis. PLoS One. 2018;13:e0200855.PubMedPubMedCentralCrossRef
44.
Ambrosio MR, Di Serio C, Danza G, Rocca BJ, Ginori A, Prudovsky I, et al. Carbonic anhydrase IX is a marker of hypoxia and correlates with higher Gleason scores and ISUP grading in prostate cancer. Diagn Pathol. 2016;11:45.PubMedPubMedCentralCrossRef
45.
Barathova M, Takacova M, Holotnakova T, Gibadulinova A, Ohradanova A, Zatovicova M, et al. Alternative splicing variant of the hypoxia marker carbonic anhydrase IX expressed independently of hypoxia and tumour phenotype. Br J Cancer. 2008;98:129–36.PubMedCrossRef
46.
Samaka RM, Abd El-Waheda MM, Al Sharaky DR, Aleskandarany MA, Shehata MA, Hegazy SE. Carbonic anhydrase IX expression and localization in breast carcinoma. Menoufia Med J. 2015;28:693–701.
47.
Koperek O, Bergner O, Pichlhöfer B, Oberndorfer F, Hainfellner JA, Kaserer K, et al. Expression of hypoxia-associated proteins in sporadic medullary thyroid cancer is associated with desmoplasticstroma reaction and lymph node metastasis and may indicate somatic mutations in the VHL gene. J Pathol. 2011;225:63–72.PubMedCrossRef
48.
Elvidge GP, Glemyl L, Appelhoff RJ. Concordant regulation of gene expression by hypoxia and 2-oxoglutrate dependantdioxygenase inhibition: the role of HIF-1, HIF-2, and other pathways. J Biol Chem. 2006;281:15215–26.PubMedCrossRef
49.
50.
Knudsen ES, Balaji U, Freinkman E, McCue P, Witkiewicz AK. Unique metabolic features of pancreatic cancer stroma: relevance to the tumor compartment, prognosis, and invasive potential. Oncotarget. 2016;7:78396–411.PubMedPubMedCentral
51.
Manish IP, Albert B, David G, Rajkumar C, David PS. Poor survival of females with bladder cancer is limited to those aged 70 years or over: a population-wide linkage study, New South Wales, Australia. Cancer Med. 2015;4:1145–52.CrossRef
52.
Liao SY, Darcy KM, Randall LM, Tian C, Monk BJ, Burger RA, et al. Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a gynecologic oncology group study. Gynecol Oncol. 2010;116:452–8.PubMedCrossRef
53.
54.
McIntyre AL, Patiar S, Wigfield S, Li JL, Ledaki I, Turley H, et al. Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy. Clin Cancer Res. 2012;18:3100–11.PubMedPubMedCentralCrossRef
55.
Eustace A, Mani N, Span PN, Irlam JJ, Taylor J, Betts NJ, et al. A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer. Clin Cancer Res. 2013;19:4879–88.PubMedPubMedCentralCrossRef
56.
57.
Cohen EN, Gao H, Anfossi S, Mego M, Reddy NG, Debeb B, et al. Inflammation mediated metastasis: immune induced epithelial-to-mesenchymal transition in inflammatory breast cancer cells. PLoS One. 2015;10(7):e0132710.PubMedPubMedCentralCrossRef
58.
Fiaschi T, Giannoni E, Taddei ML, Cirri P, Marini A, Pintus G, et al. Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells. Cell Cycle. 2013;12:1791–801.PubMedPubMedCentralCrossRef
59.
Jia L, Bickel JS, Wu J, Morgan MA, Li H, Yang J, Yu X, Chan RC, Sun Y. RBX1 (RING box protein 1) E3 ubiquitin ligase is required for genomic integrity by modulating DNA replication licensing proteins. J Biol Chem. 2011;286:3379–86.PubMedCrossRef
60.
Giannoni E, Bianchini F, Masieri L, Serni S, Torre E, Calorini L, et al. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res. 2010;70:6945–56.PubMedCrossRef
Metadata
Title
ROC-1, P21 and CAIX as markers of tumor aggressiveness in bladder carcinoma in Egyptian patients
Authors
Dalia Rifaat Al-Sharaky
Mona Abd El-Halim Kandil
Hayam Abdel Samie Aiad
Enas Megahed El-hosary
Hagar Abdelmagied Alagizy
Mahmoud Abdel-Sattar Elshenawy
Hala Said El-Rebey
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2020
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/s13000-020-00947-7

Other articles of this Issue 1/2020

Diagnostic Pathology 1/2020 Go to the issue

Case Report

Orbital involvement by NUT midline carcinoma: new presentation and encouraging outcome managed by radiotherapy combined with tyrosine kinase inhibitor: a case report

Research

Clinicopathological findings of pediatric NTRK fusion mesenchymal tumors

Research

Hepatic epithelioid hemangioendothelioma: case series of a rare vascular tumor mimicking metastases

Research

Evaluation of an online training tool for scoring programmed cell death ligand-1 (PD-L1) diagnostic tests for lung cancer

Case Report

The impact of COVID-19 on ischemic stroke

Research

Expression of RSK4, CD44 and MMP-9 is upregulated and positively correlated in metastatic ccRCC